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The 52-kDa activator protein (AP)-2 is a DNA-binding transcrip-
tion factor (Mitchell et al, 1987) which has been shown to control
transcription of several genes that are related to embryogenesis
(Mitchell et al, 1991), cancer-growth suppression or progression
(Bosher et al, 1995; Bar-Eli, 1997; Zeng et al, 1997; Turner et al,
1998). To date, three human AP-2-related genes, encoding AP-2a
(TFAP2A), AP-2b (TFAP2B) and AP-2g (TFAP2C) have been
cloned (Williamson et al, 1996).
There is increasing evidence that normal function of AP-2a is
needed in preventing the tumourigenicity and progression of cuta-
neous melanoma. The expression of AP-2 is lost in malignant
melanoma cell lines (Bar-Eli, 1997). In addition, restored AP-2a
expression inhibits growth and metastatic capacity of melanoma
cell lines through activation of proto-oncogene/tyrosine kinase
receptor c-KIT and down-regulation of MCAM/MUC18 (Bar-Eli,
1997; Huang et al, 1998; Jean et al, 1998). We recently demon-
strated in a representative clinical cutaneous melanoma material
that loss of AP-2a protein expression is associated with tumour
progression and independently predicts poor disease outcome
(Karjalainen et al, 1998). Altogether, these findings suggest that
the gene encoding AP-2a (TFAP2A) may be a tumour suppressor
in primary cutaneous melanoma.
In cutaneous melanomas genetic analyses have preferably
concentrated on cell lines and metastases due to the reduced avail-
ability of primary tumour material. To date it is not known how the
expression of AP-2a protein is down-regulated in primary cuta-
neous melanoma, and what are the critical steps involved in this
process at molecular level.
These issues are extremily important because the knowledge
of the AP-2a’s regulatory mechanisms in primary cutaneous
melanoma specimens will increase our understanding on the
melanocytic tumour progression and may thus open new thera-
peutic options in future. Therefore, we have now compared the
immunohistochemically detected AP-2a protein levels with the
corresponding AP-2a mRNA expression in consecutive tumour
areas of 52 primary cutaneous melanomas derived from our
previous larger clinical material (Karjalainen et al, 1998). In addi-
tion, we have studied whether loss of heterozygosity (LOH) at the
chromosomal location (6p24.3) (Gaynor et al, 1991) of AP-2a
gene is the mechanism responsible for the down-regulation of AP-
2a. The role of other AP-2 family members was also studied to
evaluate the importance of AP-2a in the malignant progression of
cutaneous melanoma.
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Summary The loss of transcription factor AP-2a expression has been shown to associate with tumourigenicity of melanoma cell lines and
poor prognosis in primary cutaneous melanoma. Altogether these findings suggest that the gene encoding AP-2a (TFAP2A) acts as a tumour
suppressor in melanoma. To learn more of AP-2a’s down-regulation mechanisms, we compared the immunohistochemical AP-2a protein
expression patterns with the corresponding mRNA expression detected by in situ hybridization in 52 primary melanomas. Of the 25 samples
with AP-2a protein negative areas, 16 (64%) expressed mRNA throughout the consecutive section. Nine specimens (36%) contained equally
mRNA- and protein-negative areas, suggesting that the loss of AP-2a protein associated with lack of the mRNA transcript. The highly AP-2a
protein-positive tumours (n = 27) were concordantly mRNA positive in 25 (92.6%) cases. Thirteen primary tumours were further analysed
using microsatellite markers D6S470 and D6S263 for loss of heterozygosity (LOH) of a locus harbouring TFAP2A. LOHs or chromosome 6
monosomy were found in four out of five (80%) informative AP-2a mRNA- and protein-negative tumour areas, but also within five out of 13
(38%) informative AP-2a mRNA-positive tumour areas. This chromosome region is thus suggestive of harbouring a putative tumour
suppressor gene of cutaneous melanoma, but this referring specifically to TFAP2A could not be completely verified in this analysis. We
conclude that a failure in post-transcriptional processing of AP-2a is a possible inactivation mechanism of AP-2a in cutaneous melanoma.
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Tumour material
The material of this study was derived from a large (n = 273)
earlier series of clinical stage I cutaneous melanoma patients, diag-
nosed and treated in the district of Kuopio University Hospital
between 1974 and 1989, with clinicopathological and follow-up
data available (Karjalainen et al, 1998). The starting point for the
current study was to statistically determine a cut-off level (< 75%
vs ³ 75% of AP-2a-positive cancer cells) that efficiently divided
the original (n = 273) series into low-risk (high expression, n =
169, 62%) and high-risk (low expression, n = 104, 38%) groups
(other data not shown). Based on this cut-off level, 25 high-risk
tumours with low AP-2a expression and 27 low-risk tumours with 
high AP-2a expression were selected from the original cohort 
for mRNA in situ hybridization (ISH) analyses (Table 1). As we
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Table 1 The AP-2a protein and mRNA expressions, LOH status of TFAP2A and clinicopathological features of the primary tumours
Case AP-2a mRNA/ LOHc Breslow Disease Cause of death
number protein protein- (analysed classd recurrence
expressiona concordanceb area)
1 high +/+ 4 no alive
2 high +/+ 3 no alive
3 high +/+ yes (mRNA+) 3 no other
4 high +/+ 3 no alive
5 low +/– 2 yes melanoma
6 high +/+ no (mRNA+) 3 yes melanoma
7 high +/+ 2 no alive
8 low +/– 2 no other
9 high +/+ yese (mRNA+) 4 yes melanoma
10 low +/– 3 yes melanoma
11 high +/+ 3 yes other
12 high –/+ 4 no other
13 low good homozygous 3 yes melanoma
14 low good 4 yes melanoma
15 low good no (mRNA+) 3 no alive
16 low good 2 yes melanoma
17 high +/+ no (mRNA+) 4 yes melanoma
18 low good yese,f 2 yes alive
19 high +/+ 2 no alive
20 low good yes (mRNA–) 3 no alive
21 high +/+ 2 no alive
22 low +/– homozygous 4 yes other
23 high +/+ 3 no alive
24 high +/+ 3 no alive
25 high +/+ 1 no other
26 low +/– no (mRNA+) 4 no alive
27 low +/– 3 yes melanoma
28 low +/– no (mRNA+) 3 yes melanoma
29 low +/– 2 yes melanoma
30 high +/+ 4 no alive
31 low +/– 4 yes melanoma
32 high +/+ 2 yes alive
33 high +/+ 1 yes melanoma
34 high +/+ 2 no alive
35 high +/+ 2 yes other
36 high +/+ yes (mRNA+) 3 yes melanoma
37 low +/– 4 yes melanoma
38 low +/– homozygous 3 yes other
39 high –/+ 4 yes other
40 high good nof 4 yes alive
41 low good yesg,f 4 yes melanoma
42 high +/+ 4 yes melanoma
43 low +/– 4 yes melanoma
44 low good yesg (mRNA–) 4 no alive
45 high +/+ 2 no alive
46 high +/+ 2 no alive
47 high +/+ 2 no alive
48 low good homozygous 4 no other
49 low +/– 3 yes melanoma
50 low +/– 4 yes alive
51 low +/– 4 no alive
52 low +/– 3 no alive
aHigh: ³ 75% of AP-2a protein-positive cells; low: < 75% of AP-2a protein-positive cells; b+/+: consecutive sections are completely mRNA and protein-positive;
+/–: corresponding mRNA-positive and protein-negative tumour areas; –/+: corresponding mRNA-negative and protein-positive tumour areas; good: concordant
mRNA and protein expression patterns. cLOH: loss of heterozygosity. dBreslow class: 1: ≤ 0.75 mm; 2: 0.76–1.50 mm; 3: 1.51–4.0 mm; 4: more than 4.0 mm.
eMonosomy observed. fThe same result in mRNA-positive as well as in protein and mRNA-negative areas. gMonosomy not excluded.additionally wanted to characterize the AP-2a protein and mRNA
expression levels as related to melanocytic tumour progression,
seven subsequent metastases of primary melanomas were also
studied.
Histology and immunohistochemistry
The histological and immunohistochemical (IHC) methods have
been described in detail previously (Karjalainen et al, 1998). In
brief, a rabbit polyclonal AP-2a antibody (C-18) (Santa Cruz
Biotechnology, CA, USA), raised against a peptide corresponding
to amino acids 420–437 mapping at the carboxy terminus of AP-2
of human origin (Mitchell et al, 1991), was used at a working dilu-
tion of 1:2500. The IHC method included antigen unmasking
(microwave boiling 2 ´ 5 min) and standard ABC technique
(Vectastain Rabbit ABC Elite Kit, Vector Laboratories,
Burlingame, CA, USA) to localize the bound antibody. Constantly
positive epidermal and inflammatory cells served as excellent
positive internal controls. Melanoma specimens known to be
positive for AP-2a were used as additional positive controls. In
each batch, a primary melanoma specimen incubated without
primary antibody was used as a negative control. Eighteen
tumours were stained using the same staining protocol with
human AP-2b and AP-2g specific antibodies (C-20 and T-17,
Santa Cruz Biotechnology, CA, USA) at working
dilutions of 1:200.
mRNA in situ hybridization
Deparaffinized 5-mm sections were microwaved in 0.01 M citrate
buffer (pH 6.0) for 5 min. The samples were fixed in 4%
paraformaldehyde for 20 min, rinsed, pretreated with 0.1 M
hydrochloric acid (HCl) and phosphate-buffered saline (PBS),
followed by digestion for 20 min with proteinase K (Boehringer
Mannheim, Germany) at the concentration of 20 mg ml–1. After a
short fixation by 4% paraformaldehyde, the sections were rinsed in
PBS and in 0.85% sodium chloride (NaCl), dehydrated in graded
ammonium acetate alcohols and air-dryed. All specimens were
then prehybridized for 2 h at 62°C. Recombinant plasmid pHAP2-
Hsma containing human AP-2a exon 2 (transactivation domain) in
a pBluescript KS+-vector was linearized to generate antisense- and
sense-digoxigenin-labelled probes by DIG RNA labelling Kit
(Boehringer Mannheim, Germany). The AP-2a exon 2 region
selected for this study is relatively poorly conserved with short
amino acid motifs only, and at the RNA level the homology is
minimal within the other AP-2 family members. Under the condi-
tions used in this study the probe is thus very unlikely to cross-
hybridize to anything else but AP-2a RNA. Probes were added to
the hybridization buffer at 5 ng ml–1 and the sections were
hybridized overnight at 62°C in a humified chamber.
Subsequently, the sections were washed with increasing strin-
gency. Non-specific binding was blocked with 2% normal sheep
serum (Sigma, UK) in 0.1% Triton X/TBS-buffer. The hybridized
probe was detected by incubation in anti-digoxigenin alkaline
phosphatase conjugate (Boehringer Mannheim, Germany)
followed by NBT/BCIP. The reaction was stopped with diluted
water, sections were dehydrated and coverslipped with Mountex
(Histolab Production AB, Sweden). Consecutive sections of 
each specimen, stained using the sense probe, served as 
negative controls and remained negative throughout the series
(Figure 1E).
Microdissection
Twenty-five paraffin-embedded samples were microdissected to
be used for the LOH analyses. The microdissection was made
using a 24 G needle under a light microscope in carefully matched
tumour areas containing at least 70% of tumour cells. Normal
tissue was obtained from the same preparates. From each spec-
imen, five 20-mm-thick consecutive sections were subjected to
DNA extraction. Whenever possible, the tumour areas that
displayed no protein and mRNA signal for AP-2a, as well as the
areas being positive for AP-2a mRNA, were separately microdis-
sected and analysed. Finally, two AP-2a mRNA-positive paraffin-
embedded samples were microdissected for reverse transcription
polymerase chain reaction (RT-PCR) analyses.
RT-PCR amplification
To study the expression of AP-2a mRNA, the total cellular RNA
was extracted from five 20-mm-thick paraffin-embedded tissue
sections of the tumour as described previously (Sugg et al, 1998).
The RNA was used as a template to synthesize first-strand cDNA
and PCR amplification was performed using the commercially
available Enhanced Avian RT-PCR kit (Sigma, USA). The
primers for the AP-2a were designed to anneal to exon 2 of the
TFAP2A gene. The specific primers used were: AP-2 U 5¢-GCCC-
CGTGTCCCTGTCCAA-3¢ and AP-2 L 5¢-TGAGGAGCGA-
GAGGCGACC-3¢. PCR products were electrophoresed on a 6%
polyacrylamide gel, stained with ethidium bromide and visualized
under UV-light.
LOH analysis
DNA was extracted by proteinase-K–phenol–chlorophorm method
following standard protocols (Isola et al, 1994). Two TFAP2A-
adjacent microsatellite markers, D6S470 (6.3 cM from TFAP2A)
and D6S263 (7.9 cM from TFAP2A) were used to evaluate the
frequency of LOH in AP-2a locus. These markers were chosen
from the http://cedar.genetics.soton.ac.uk. Two other markers,
D6S1027 and D6S1021, mapped to the long arm of chromosome 6
and were used to evaluate loss of the whole chromosome. Primer
sequences and PCR amplification conditions to these markers
were obtained from http://www.gdb.org. The forward primers
were labelled either with fluorescent dyes 6-FAM or TET. The
target sequences were amplified by PCR in a total volume of 20 ml
with Ampli Taq Gold polymerase (Perkin-Elmer, Foster City,
USA) following manufacturer’s recommendations. Fragment
analysis was done utilizing ABI PRISM 310 genetic analyser
(Perkin-Elmer, Foster City, CA, USA).
LOH was calculated from the informative cases, i.e. where two
alleles could be seen on the DNA obtained from normal tissue.
Because PCR fragments of different sizes are amplified with
different efficiences, the ratio of allele peak heights was calculated
in matched normal and tumour DNA samples. The LOH-value was
calculated using formula LOH=(T2 ´ N1)/(T1 ´ N2), where T is a
tumour allele and N a normal tissue allele. A value under 0.6 or
greater than 1.67 was assessed LOH (Canzian et al, 1996).
RESULTS
AP-2a protein expression
In AP-2a immunohistochemistry, the normal epidermis 
stained positively throughout the series. In the specimens 
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contained less than 75% and 27 primary melanomas contained
more than 75% of positively stained tumour cells within 
a section.
AP-2a mRNA expression
The mRNA signal was seen intracellularly as distinct blue dots
(Figure 1A). The adjacent normal epidermis was constantly mRNA
positive throughout the series. Of the 52 primary cutaneous
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Figure 1 AP-2a mRNA and protein expression as well as TFAP2A’s LOH status in tumour areas of consecutive sections of the primary melanoma number 44.
(A, C, E:) mRNA in situ hybridization; (B, D) immunohistochemistry. (A) mRNA-positive tumour area. Asterisk indicates normal epidermis. Bar = 40 mm.
(B) Protein-positive tumour area. Asterisk indicates normal epidermis. Bar = 40 mm. (C) mRNA-negative tumour area. Bar = 40 mm. (D) Corresponding protein-
negative tumour area as seen in C. Bar = 60 mm. (E) Corresponding tumour area to A stained using the sense probe (T7) as a negative control. Asterisk
indicates normal epidermis. Bar = 80 mm. (F) Results of LOH analysis between the mRNA expressing (A, B) and mRNA non-expressing (C, D) tumour areasmelanomas, 40 cases (77%) expressed mRNA throughout the
section, and a focal staining pattern (containing also mRNA-nega-
tive areas) was observed in 12 (23%) cases (Table 2). RT-PCR
from AP-2a mRNA- and protein-positive paraffin-embedded
tumour tissues confirmed that the positive signal in ISH originated
from the exon 2 of TFAP2A, instead of genomic sequences of AP-
2b or artifacts in tissue processing (Figure 2).
The relation of AP2-a mRNA to protein expression
In the subgroup of low AP-2a protein expression (n = 25), 16
(64%) cases were completely mRNA-positive. Nine specimens
(36%) displayed similar AP-2a protein and mRNA expression
patterns, including concordantly mRNA- and protein-negative
tumour areas. The highly AP-2a protein-positive tumours (n = 27)
were equally mRNA-positive in 25 (93%) cases. The two
remaining specimens (7%) included AP-2a protein-positive areas
without corresponding mRNA signal (Table 2).
LOH analysis of TFAP2A
PCR-amplification was successful in a total of 17 primary cuta-
neous melanomas of which 13 (including 18 separately analysed
tumour areas) were informative in the LOH analysis. LOH or loss
of the chromosome 6 (monosomy) were found in 7/13 (54%) of all
informative primary melanomas. Six out of seven of these chro-
mosomal changes were found in tumours more than 1.5 mm in
Breslow thickness (Table 1). There were five concordantly mRNA
and protein negative areas in five tumours. These areas harboured
LOH or monosomy in four cases (80%). On the other hand, all 13
tumours included mRNA-positive areas, which harboured two
LOHs and three apparent monosomies (Figure 1F, Tables 1 and 3).
Metastatic lesions
Seven metastatic lesions were assessed for their AP-2a protein and
mRNA status. The metastases had a smaller AP-2a protein-posi-
tive cell fraction than their corresponding primary tumours in four
specimens. In one case the fractions of AP-2a protein-positive cells
were equal, and in two cases the metastatic lesion had a higher
number of AP-2a protein-positive cells than the corresponding
primary tumour. The comparison of consecutive sections revealed
mRNA without concomitant protein expression in four specimens.
ISH and IHC sections were thoroughly positive in two specimens
and one case displayed similar mRNA and protein expression
patterns. This specimen had LOH only in the negative area.
DISCUSSION
The present study showed that in the majority (64%) of the
primary melanomas with reduced AP-2a protein expression the
tumour tissue still contained AP-2a mRNA. This finding suggests
that the AP-2a mRNA expression can be uncoupled from the AP-
2a protein expression in primary cutaneous melanoma. Similarly,
Butz et al (1998) found substantial discrepancies between intracel-
lular p21 mRNA and protein levels in SW756 carcinoma cell lines
under genotoxic stress. Our finding can be explained at least by
two different ways. First, the AP-2a mRNA may not have been
adequately translated into protein. This could be due to impaired
post-transcriptional processing of the mRNA-transcript (Kleijn et
al, 1998), or due to repression in translation initiation which is
controlled by specific RNA–protein interactions (Day and Tuite,
1998; Kleijn et al, 1998). Also alternatively spliced AP-2a variant
(Buettner et al, 1993) or specific translation inhibitory elements
(Wang et al, 1997; Liu and Redmond, 1998) may function as
translational repressors. Another possible reason for our result is
premature truncation of the AP-2a protein which may affect the
antibody affinity, or degradation of the AP-2a protein.
Because chromosomal deletions of a single allele copy (LOH)
together with an inactivating point mutation in the remaining allele
may result in loss of a proper gene product, and because LOHs
may well point to possible tumour suppressor genes (Knudson,
1971; Baker et al, 1989; Levine and Momand, 1990; Sellers and
Kaelin, 1997), we wanted to see whether the absence of AP-2a
mRNA could be a consequence of LOH in the vicinity of
TFAP2A. Ten primary cutaneous melanomas and one metastasis
included well-matching protein and mRNA-negative areas, being
potential candidates for LOH. Indeed, we found allelic loss in four
out of five informative primary specimens and in the metastatic
AP-2 in cutaneous melanoma 2019
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Table 2 The comparisons of AP-2a mRNA and AP-2a protein expression
patterns in consecutive sections of 52 primary cutaneous melanomas
mRNA mRNA concordant mRNA- and protein
positivea negativeb expression patternsc
AP-2a protein nn n
expression
< 75% (low) 16 – 9
³ 75% (high) 24 2 1
Total 40 2 10
amRNA-positive areas without concomitant protein expression. bProtein-
positive areas without concomitant mRNA expression, cases 12 and 39.
cCorresponding mRNA and protein-positive as well as -negative areas.
L 9 51 (–) (+)
140 bp
118 bp
110 bp
132 bp=AP-2a
Figure 2 Expression of AP-2a mRNA in cutaneous melanoma (cases 9
and 51). Exon 2 region of the TFAP2A gene was analysed by RT-PCR. The
far left (L) line contains a size ladder indicating molecular weight, (–) depicts
a negative control in which a template was replaced by water (H2O), (+) is a
positive control for AP-2a RNA (from Clontech Human Lung cDNA Library).
Both cases (9, 51) contain PCR product of the same molecular size (132 bp)
as the positive control sample
Table 3 The findings of LOH analysis of TFAP2A according to AP-2a
mRNA status in 18 analysed tumour areas in 13 primary cutaneous
melanomas (only informative cases included)
LOHa
Areas Yes No
(n)( n)( n)
mRNA-positive 13 5b 8
mRNA-negative 5 4c 1
Total 18 9 9
aLoss of heterozygosity. bIncludes two cases with monosomy and one case in
which monosomy could not be excluded. cIncludes one case with monosomy
and two cases in which monosomy could not be excluded.lesion, but we could not exclude loss of the whole chromosome in
three of these cases with control markers mapping to 6q. Thus,
LOH or monosomy of chromosome 6 seem to be quite frequent
if the down-regulation of AP-2a protein is associated with the
absence of AP-2a mRNA.
The genetic effect of chromosome 6 to melanoma was originally
depicted by Trent et al with an observation that reintroduction of
chromosome 6 into metastatic melanoma cells inhibited their
tumourigenicity and metastatic potential (Trent et al, 1990). The
long arm of the sixth chromosome (6q) is known to harbour LOH
frequently in cutaneous melanoma (Millikin et al, 1991; Walker et
al, 1994; Robertson et al, 1996; Slominski et al, 1998) and in other
cancers (Foulkes et al, 1993; Noviello et al, 1996). So far, chromo-
somal losses confined specifically to the short arm of the chromo-
some 6 (6p) near the location of TFAP2A in 6p24 have been
documented in melanoma cell lines (Real et al, 1998; Turner et al,
1998) and in several other malignancies (Foulkes et al, 1993). As far
as the authors are aware, the present study is the first one to reveal
LOHs confining specifically to 6p in primary cutaneous melanoma.
There were five LOHs (including three apparent monosomies)
within the 13 informative mRNA-positive primary tumour areas
(Table 3). This finding is similar to a previous observation of func-
tional RB protein despite LOH of the RB locus (Dodson et al,
1994). Our findings suggest that the investigated chromosome
region around TFAP2A locus or more distant regions in chromo-
some 6 may contain other putative tumour suppressor genes that
have a role in melanoma progression. There were three cases
(numbers 12, 39 and 40) with unexpected results in the analyses.
The discrepancy between mRNA and protein expression in cases
12 and 39 could theoretically be explained by prolonged protein’s
half-life, autoregulation mechanisms suppressing AP-2a’s mRNA
expression (Imhof et al, 1999) or alternative mRNA splicing
affecting the mRNA ISH probe affinity (Meier et al, 1995;
Ohtaka-Maruyama et al, 1998). It is also possible that the absence
of AP-2a mRNA in the case number 40 is due to other genetic
inactivation mechanisms than LOH, such as gene methylation
(Gonzalgo et al, 1997) or mutations affecting both gene alleles
(Levine and Momand, 1990; Sellers and Kaelin, 1997). Being rare
these three cases do not influence the main conclusions of the
current study, but the possible role of these mechanisms should be
studied in future.
To further evaluate the role of other AP-2 family proteins
(Turner et al, 1998) in the present series, we tested primary cuta-
neous melanoma specimens with high and low AP-2a protein
expression for their AP-2b and AP-2g expression. Despite a weak
cytoplasmic signal with both antibodies in less than half of the
cases, none of the tumours displayed any nuclear positivity (data
not shown). The AP-2a-specific RT-PCR further confirmed that
the positive mRNA signal seen with ISH originated from AP-2a.
Supporting our finding, AP-2a has also been demonstrated to be
the principal AP-2 form in keratinocytes by Northern blots
(Bossler AD et al, manuscript in preparation). Thus, it seems that
the immunopositivity detected by C-18 antibody represents mainly
AP-2a, and that AP-2a is the most important AP-2 gene family
member related to the progression of skin melanoma.
Our results suggest that the expression of AP-2a protein in
melanoma is mainly under post-transcriptional control, and the
absence of mRNA seems to comprise the remaining one-third of
the clinically significant down-regulation. When mRNA was not
detected, specific LOH for the 6p arm or monosomy was frequently
(80%) encountered. According to our results, LOH within
TFAP2A-adjacent area is a late phenomenon in melanoma progres-
sion. The finding of AP-2a mRNA and protein despite simulta-
neous LOH suggests that there may be a new putative tumour
suppressor gene within close vicinity of TFAP2A. In addition to
these novel findings our study has opened many questions which
need to be answered in future studies to understand more precisely
the role of AP-2a in cutaneous melanoma.
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